Plain-English translation of NCT07319897 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new diagnostic imaging scan called 68Ga-BCMA PET/CT that helps doctors see where myeloma cancer cells are located throughout your body. The scan uses a special radioactive tracer that attaches to a protein found on myeloma cells, making them visible on imaging. Researchers want to understand how well this new scan works compared to standard tests and biopsies, and whether it can help doctors better understand your disease and guide treatment decisions.
Currently, doctors use multiple different tests and biopsies to find and monitor myeloma, which can be time-consuming and invasive. This trial exists to see whether this new scanning technology could provide a faster, non-invasive way to map the full extent of myeloma throughout your body in a single test.
You likely qualify if…
You likely don't qualify if…
You will receive one PET/CT scan using the new 68Ga-BCMA imaging tracer, performed according to a standard protocol. The scan itself typically takes 30 minutes to an hour. You may also have blood samples drawn to measure certain markers in your blood, and your imaging results will be compared with any biopsies or other tests you're having done. The research team will follow up with you over time to see how the scan results relate to your treatment response and disease course.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
China